ReviewBiomedicines2020
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications.
Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Epigenetic reprogramming and antitumor immune responses in gliomas: a systematic review.Medical oncology (Northwood, London, England) · 2025Pooled it
- Clinicopathological Implications of IDH1 Mutation and Ki-67 Expression Across WHO Grades of Gliomas: Insights from a Prospective Observational Study.Iranian journal of pathology · 2026Article
- Unconventional guardians of the brain: MAIT cells as emerging players in glioblastoma immunity.Frontiers in immunology · 2026Review
- Decoding Multi-Omics Signatures in Lower-Grade Glioma Using Protein-Protein Interaction-Informed Graph Attention Networks and Ensemble Learning.Diagnostics (Basel, Switzerland) · 2025Article
- Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.PharmacoEconomics - open · 2025Article
- From pixels to prognosis: leveraging radiomics and machine learning to predict IDH1 genotype in gliomas.Neurosurgical review · 2025Article
- Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions.Cells · 2025Review
- Poor diagnostic value of isocitrate dehydrogenase 1 R132H immunohistochemistry for determination of isocitrate dehydrogenase 1 status in patients with glioblastoma.Surgical neurology international · 2025Article
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- Intra-tumoral susceptibility signals in brain gliomas: where do we stand?Frontiers in radiology · 2025Review
- Regulation of autophagy by non-coding RNAs in human glioblastoma.Medical oncology (Northwood, London, England) · 2024Review
- Neurosurgical management of primary and secondary brain tumors: new horizons and emerging strategies.Neurosurgical review · 2024Article
- Analysis of IDH and EGFR as biomarkers in glioblastoma multiforme: A case-control study.Heliyon · 2024Article
- Flavopiridol Suppresses Cell Proliferation and Migration and Induces Apoptotic Cell Death by Inhibiting Oncogenic FOXM1 Signaling in IDH Wild-Type and IDH-Mutant GBM Cells.Molecular neurobiology · 2024Article
- Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy.International journal of molecular sciences · 2024Review
- IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.BMC cancer · 2024Article
- The mutated in colorectal cancer (Frontiers in oncology · 2024Article
- IDH-mutant gliomas in children and adolescents - from biology to clinical trials.Frontiers in oncology · 2024Article
- Fibronectin Type III Domain Containing 3B as a Potential Prognostic and Therapeutic Biomarker for Glioblastoma.Biomedicines · 2023Article
- Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Mutations in isocitrate dehydrogenase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.